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SUMMARY
BACKGROUND AND OBJECTIVES: Osteoarth-
ritis (OA) is the most common arthropathy and one 
of the major causes of chronic pain in the elderly 
population, which may lead to major functional 
incapacity of these individuals. Aiming at treating 
pain of elderly patients with knee OA, we have used 
lysine clonixinate (LC) and have evaluated its ef-
fectiveness
METHOD: Randomized, double-blind, placebo-
controlled clinical trial with 109 elderly patients 
with knee OA-related pain. Participants were dis-
tributed in two groups: Group LC and Group P (pla-
cebo), who received tablets to be used three times 
a day for 30 days. Evaluations were performed in-
itially, 15 days after and at study completion, as to 
pain intensity at rest, at initial movement, ambula-
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tion and joint compression; and the need for addi-
tional analgesia, morning stiffness; pain-related 
functional incapacity, adherence, tolerability and 
global treatment evaluation.
RESULTS: LC has significantly decreased pain 
at initial movement and ambulation already in the 
first 15 days, with 30% decrease in protokinetic 
pain and 31.6% in ambulation, but best results were 
seen after 30 days, when reductions were 42.3% and 
45.5%, respectively. Additional analgesia was sig-
nificantly lower with LC: 2.6% and 9.5% for groups 
LC and P, respectively. There were no differences 
between groups in morning stiffness and functional 
incapacity. There has been major adherence and tol-
erability. Global evaluation was favorable to LC, 
being excellent or good for 50% of patients.
CONCLUSION: Lysine clonixinate was effective 
to treat knee OA-related pain in elderly people. 
Keywords: Analgesia, Elderly, Knee, Lysine clon-
ixinate, Osteoarthritis.
RESUMO
JUSTIFICATIVA E OBJETIVOS: A osteoartrose 
(OA) é a artropatia mais comum e uma das prin-
cipais causas de dor crônica na população idosa, 
podendo levar a grande incapacidade funcional 
nestes indivíduos. Objetivando o tratamento da dor 
em idosos com OA de joelho utilizou-se o clonix-
inato de lisina (CL) e avaliou-se a sua efetividade.
MÉTODO: Estudo clínico e duplamente encoberto, 
aleatório e placebo controlado com 109 idosos com 
dor associada à OA de joelho. Os participantes foram 
divididos em dois grupos: Grupo CL e P (placebo) 
que receberam comprimidos para uso três vezes ao 
dia por 30 dias. Realizadas avaliações iniciais, após 
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15 dias e ao final do estudo, quanto à intensidade de 
dor em repouso, ao movimento inicial, à deambula-
ção e à compressão articular; necessidade de anal-
gesia complementar, rigidez matinal; incapacidade 
funcional associada à dor, aderência, tolerabilidade 
e avaliação global do tratamento.
RESULTADOS: O CL reduziu significantemente 
a dor ao início do movimento e à deambulação já 
nos primeiros 15 dias, redução de 30% da dor pro-
tocinética e de 31,6% à deambulação, mas os mel-
hores resultados ocorreram com 30 dias, quando as 
reduções foram de 42,3% e 45,5%, protocinética e à 
deambulação, respectivamente. A analgesia comple-
mentar foi significantemente menor com o CL: 2,6% 
e 9,5%, grupos CL e P, respectivamente. Não ocor-
reram diferenças entre os grupos para rigidez matinal 
e incapacidade funcional. Houve grande aderência e 
tolerabilidade. A avaliação global foi favorável para 
o CL, sendo excelente ou boa em 50%. 
CONCLUSÃO: O clonixinato de lisina foi efetivo 
no tratamento da dor associada à osteoartrite de 
joelho em idosos.
Descritores: Analgesia, Clonixinato de lisina, 
Idoso, Joelho, Osteoartrose.
INTRODUCTION
Increased life expectancy is related to a higher 
prevalence of chronic health problems and asso-
ciated functional incapacities, which are natural 
consequences of population ageing1. Among these, 
there is osteoarthritis (OA), a universal disease 
with high incidence especially among the elder-
ly. It is the most common arthropathy2 and may 
lead to major incapacity, especially when affect-
ing joints bearing weight, such as knees and hips. 
Its prevalence increases with age, being observed 
radiographic OA changes in up to 85% of people 
above 75years of age2,3.
Knee OA is more common than hip OA, its symp-
toms are in general more severe and it causes major 
morbidity, especially with regard to pain and func-
tional incapacity which are present in more than 
17% of individuals aged between 65 and 74 years2,3.
OA therapy has gone through major advances in 
recent years, but there are still not well-designed 
clinical trials with enough duration which show 
important pharmacological effects to change the 
disease, that is, there are still no drugs proven to 
be able to prevent, avoid or revert cartilage lesions 
in humans4. So, being impossible to cure OA, de-
creasing pain and associated functional incapacity 
becomes the major therapeutic objective.
For many patients, OA pain relief with analgesics 
such as acetaminophen is comparable to the relief 
obtained with non-steroid anti-inflammatory drugs 
(NSAIDs)4,5; however in a meta-analysis involving 
knee OA clinical trials where simple analgesics 
and NSAIDs were used, it has been observed that 
analgesia induced by the latter was significant-
ly better7. NSAIDs are more widely used in OA 
with satisfactory response even when there are no 
inflammatory signs4
Lysine clonixinate (LC) is an anti-inflammatory an-
algesic with chemical origin in the carboxylic acids 
group and is characterized by having intense cen-
tral and peripheral analgesic power and lower anti-
inflammatory action8. Its action mechanism is char-
acterized by the reversible inhibition of cycloxy-
genase, which blocks prostaglandins synthesis, and 
by the antagonism to prostaglandins8. This dual 
action may explain the relatively weak correlation 
between prostaglandins synthesis inhibition and the 
anti-inflammatory power in vivo. A study has shown 
that LC is a weak cycloxygenase inhibitor and acts 
especially in blocking cycloxygenase 29. Its action 
on the central nervous system is suggested by the 
presence of major analgesic effect, similar to opi-
oids. This intense antinociceptive action depends 
on the presence of inflammatory or hyperalgic pro-
cess, which is still not very clear. The interaction 
of LC with central opioid receptors is suggested, 
although an action mediated by these receptors has 
not yet been evidenced10.
Although the lack of cost-effectiveness studies 
comparing LC to other NSAIDs, the use of LC in 
the clinical practice is considered of lower cost as 
compared to coxibs, which are included as alterna-
tive to patients at risk for adverse upper gastro-
intestinal tract events11.
Several studies have evaluated the use of NSAIDs 
for knee OA, but few have exclusively addressed the 
elderly population. Unique LC characteristics were 
shown in several studies11,12, such as high analgesic 
efficacy regardless of the presence of inflammatory 
or hyperalgic processes, lack of significant adverse 
effects and low cost.
The major aim of our study was to evaluate LC ef-
fectiveness as compared to placebo (P) to treat pain 
in elderly people with knee OA.
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The potential risk for adverse gastrointestinal and 
renal effects with the prolonged use of NSAIDs in 
the elderly population is well known11 so the symp-
tomatic treatment of OA using NSAIDs should last 
for a short period. So, we decided for a 30-day per-
iod study. Today it is very important to carry out 
studies addressing analgesia in the elderly popu-
lation, especially those involving effective drugs 
with less undesirable effects, such as cardiovascu-
lar events, which are frequently observed with the 
use of coxibs14, drugs with analgesic effects and 
less gastrointestinal effects, but of limited use for 
those with increased cardiovascular risk, such as 
the elderly.
METHOD
After the Institution’s Research Ethics Commit-
tee approval (Process 97/23-09), this double-blind, 
randomized and placebo-controlled study was car-
ried out. Studied sample was obtained from the Ser-
vice of Osteoarticular Diseases and Pain, Federal 
University of São Paulo (UNIFESP).
Participated in the study 109 elderly patients with 
knee OA-related pain. Inclusion criteria were age 
equal to or above 60 years; both genders and any 
ethnical group; diagnosis of idiopathic knee OA 
(femorotibial compartment), with at least one af-
fected knee, clinically and radiologically confirmed 
by the American College of Rheumathology (ACR) 
criteria3; pain in the knee (for at least 3 months) at 
rest or moving, with intensity equal to or above 30 
mm in the pain visual analog scale (VAS)8; lack of 
diseases which could change the follow-up of the 
study; understanding and motivation, in the inves-
tigator’s opinion, to complete the study, free and 
informed signed consent, according to clinical re-
search best practices.
Exclusion criteria were history of allergy or in-
tolerance to LC or other NSAIDs; history or pres-
ence of peptic ulcers in the last 12 months; history 
of gastrointestinal hemorrhage; kidney or liver 
disease, or even intestinal inflammatory disease; 
connective tissue disease. Psoriasis or porphyry; 
current alcoholism history; use of NSAIDs in the 
last seven days; meniscopathies, concomitant bur-
sitis or tendonitis; use of steroids by any route in 
the last 2 months; use of anticoagulants; inflamma-
tory, infectious, microcrystalline, metabolic and 
hematological diseases, arthropathies by avascu-
lar and tumor necrosis; obesity with body mass 
index (BMI) higher than 40; severe uncontrolled 
chronic diseases (hypertension, diabetes mellitus, 
heart disease and other diseases which, by their 
nature or proposed treatment, could interfere, 
in the investigator’s opinion, with the proposed 
evaluation); presence of important joint deviation 
in the affected knee and / or with surgical indica-
tion; presence of thigh arthritis or ankle or foot 
arthritis. Initial evaluation followed the sequence 
below: 1. Clinical observation and confirmation of 
knee OA diagnosis. 2. Signature of the Free and 
Informed Consent Term (FECT). 3 Knee pain in-
tensity evaluation. 4. Evaluation of morning joint 
stiffness. 5. Evaluation of pain-related functional 
incapacity. 6. Randomization and 7. Delivery of 
drugs and instructions about their use, as well as 
the use of additional analgesia.
VAS was used for different situations to evaluate 
knee pain intensity: pain at rest, at initial move-
ment, at ambulation and at joint compression.
Morning joint stiffness was measured by its dur-
ation, being used a 4-point scale: 0 = less than one 
minute, 1 = from one to 15 minutes, 2= 16 to 30 
minutes, 3 = more than 30 minutes. For pain-related 
functional incapacity patients were asked whether 
knee pain was associated to any impairment in 
daily activities (DA), following the questions of the 
“Older American Resources and Services – OARS 
– Methodology”16 for functional incapacity in the 
elderly. Then, functional incapacity was classified 
in: Class 1: pain did not cause any damage to DA, 
Class 2: pain caused damage to few DA (two activ-
ities), Class 3: pain caused severe damage to DA 
(three activities), Class 4: pain caused severe in-
capacity for DA (four or more activities).
Groups were randomly formed. Participants re-
ceived a bottle with 90 tablets with 125 mg LC 
or P and were instructed about oral administration 
every eight hours for 30 days. They were also in-
structed to use additional analgesia being allowed 
oral analgesia with dipirone or acetaminophen, 
if needed. They were not allowed throughout the 
study to use NSAIDs, steroids, myorelaxants, opi-
oids, phytotherapeutic drugs or local treatment 
with analgesics.
Two control evaluations were made at 15 days 
interval (visit 2 and visit 3), for clinical exams and 
pain, joint stiffness, pain-related incapacity re-
evaluations and to check the need for additional an-
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algesia. Adhesion to treatment and tolerability were 
also checked.
LC analgesic effectiveness was established ac-
cording to the following parameters: improved 
pain at rest, at initial movement, at ambulation, 
at joint compression and the need for additional 
analgesia.
For adhesion to treatment we asked about the use 
of the drugs in prescribed doses and forms. At the 
end of the study, bottles still with tablets were 
counted and remaining tablets were recorded. Ad-
hesion to treatment was considered good when 
there was no treatment interruption. When patients 
did not show up for the control evaluations, all ef-
forts were made to contact them and find out the 
reasons for the absence: lack of efficacy, adverse 
events or even other reasons.
To evaluate tolerability, clinical adverse events 
were asked, followed by a structured questionnaire: 
presence of pyrosis, heartburn, nausea, vomiting, 
epigastric pain, intestinal bleeding, hematemesis, 
epigastric plenitude, diarrhea, headache and dizzi-
ness. If present, their intensity was recorded (mild, 
moderate or severe). Adverse clinical events were 
also spontaneously reported.
The investigator gave his opinion about the global 
treatment evaluation at the end of the study. This 
evaluation was classified as: very bad, bad, regular, 
good or excellent treatment.
Pearson’s Chi-square, Student’s t and Wald tests 
were used for statistical analysis of results. In all 
cases, rejection level for null hypothesis was always 
established as lower than or equal to 0.05 (5%).
RESULTS
Study sample was composed of 109 elderly patients, 
63 in LC group and 46 in P group. From these, 12 
have not completed the study, 5 in LC group and 7 
in P group (reasons were unwillingness to continue 
the study).
Mean age was 72 years for LC group and 73 years 
for P group, without statistically significant differ-
ence between groups. Most were females (88.1%); 
96.3% in LC groups and 80.4% in P group. Few 
males participated in the study and, in spite of the 
significant difference in this data (p = 0.042), this 
was not relevant for statistical analysis. As to race, 
82.5% were Caucasians, 14.5% were Blacks and 
2.8% were Yellow, without statistical difference 
between groups (p = 0.911).
As to pain intensity in different situations, means in 
the beginning of the study were: 6.7 mm at rest for 
LC group and 8.9 mm for P group, 83 mm at initial 
movement for LC group and 78.5 mm for P group; 
74.1 at ambulation for LC group and 70.9 mm for 
P group and 35.4 m at joint compression for LC 
group and 35.9 for P group (Table 1). There were no 
significant differences between groups in this par-
ameter, except for pain at ambulation, which was 
higher in LC group (p = 0.049).
Morning stiffness was not present in 52.% and 
32.6% of LC and P groups, respectively, and when 
present it was brief, that is, pain lasting for 1 to 15 
minutes (36.5% in LC groups and 54.4% in P group, 
p = 0.081).
As to pain-related incapacity, most patients pre-
Table 1 – Characterization of the sample according to pain intensity in different situations and according to pain-related incapacity
Groups  Pain Intensity (mm) 
 Rest Initial Mov. Ambulation Compression
 (mean) (mean) (mean) (mean)
LC 6.7 83.0 74.1 35.4
P 8.9 78.5 70.9 35.9
Total 7.8 80.7 72.5 35.6
p Value 0.079 0,163 0.049 0.456
Pain-Related Incapacity
 1 2 3 4 Total
 n(%) n(%) n(%) n(%) n(%)
LC 19 (30.2) 28 (44.4) 14 (22.2) 2 (3.2) 63 (100)
P 17 (36.7) 19 (41.3) 9 (19.6) 1 (2.2) 46 (100)
Total 36 (33.0) 47 (43.1) 23 (21.1) 3 (2.8) 109 (100)
p Value = 0.786
1 = pain does not cause any incapacity; 2 = pain causes minor incapacity (impairment of 2 DA); 3 = pain causes considerable 
incapacity (impairment of 3 DA); 4 = pain causes major incapacity (impairment of 4 or more DA).
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Graph 2 – Pain means at ambulation along visits, according to 
each studied group.
Wald Test: interaction between groups; p < 001
Pain decrease Group LC Group P
(visit 1 x visit 2) p < 0.001 p = 0.009
(visit 1 x visit 3) p < 0.001 p < 0.027
(visit 2 x visit 3) p = 0.002 p = 0.951
sented mild incapacity (44.4% in LC group and 
41.3% in P group, p = 0.786) (Table 1).
About LC analgesic effectiveness, it was not more 
effective than P to decrease pain at rest (p = 0.079), 
but for pain at initial movement, groups had dif-
ferent behaviors along the study (“interaction ef-
fect” between time and groups in statistical lan-
guage) (Graph 1). With LC, this pain decreased in 
average 30% in the first 15 days, with statistically 
significant difference (p < 0.001) and 12.3% more 
from there on, also with significant decrease (p < 
0.001). P group had significant decrease of 13.5% 
only in the first 15 days (p = 0.006), but then it re-
mained unchanged (p = 0.287). There has been an 
“interaction effect” because behavior of groups has 
changed, that is, along time groups have “changed 
position” and the LC group started to show a lower 
pain mean as compared to P group (p = 0.001).
The same was true with pain at ambulation, as 
shown in graph 2. Here we have also observed dif-
ferent behaviors of groups, that is, there has been 
also the “interaction effect”. It has been observed 
that the LC group has significantly decreased pain 
at ambulation in 31.6% in the first 15 days (p < 
0.001) and 13.9% more from this point until the end 
of the study (p = 0.002). There has been a signifi-
cant decrease of 12.8% in P group during the first 
15 days (p = 0.009) but then it has not been further 
decreased (p = 0.951). So, according to the “inter-
action effect” LC was more effective than P for pain 
at ambulation analgesia.
As to joint compression, groups had the same be-
havior along the treatment (p = 0.456). The same 
was true for morning joint stiffness, that is, LC was 
not more effective to decrease morning stiffness (p 
= 0.081).
As to additional analgesia, 26.1% of P group has 
received it as compared to only 9.5% of LC group 
with statistically significant difference (p = 0.021).
In terms of pain-related functional incapacity, there 
has been no change in both groups, that is, there 
were no different behaviors along the study be-
tween groups (p = 0.786) (Graph 3).
Graph 3 – Means of pain-related incapacity along the study, 
according to each studied group.
Wald Test: pain-related incapacity; p = 0,786
Groups LC and P:
(visit 1 x visit 2) p = 0.317
(visit 1 x visit 3)  p < 0.001
(visit 2 x visit 3)  p < 0.001
Graph 1 – Pain means at initial movement along the study, ac-
cording to each studied group.
Wald test: interaction between groups; p = 0,001
Pain decrease Group LC Group P
(visit 1 x visit 2) p < 0.001 p = 0.006
(visit 1 x visit 3) p < 0.001 p < 0.001
(visit 2 x visit 3) p < 0.001 p = 0.287
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In global treatment evaluation there has been statis-
tically significant difference between groups, with 
a significantly more favorable evaluation for LC, 
being that 50% of such group had global evaluation 
classified as good or excellent, while only 21.1% of 
P group had the same evaluation (p = 0.010). And 
more, P group had more global evaluations classi-
fied as very bad or bad (57.9% P versus 34.5% LC).
All patients who completed the study used the drug 
correctly so the adhesion to treatment was con-
sidered very good.
There were 37.9% adverse reactions in LC group 
as compared to 23% in P group, without signifi-
cant differences between groups (p = 0.124). Major 
reactions were: epigastric pain, heartburn, pyrosis, 
nausea, dizziness, headache, lower limbs edema, 
pruritus and sleepiness. Reactions were mainly of 
mild to moderate intensity. There was one case of 
mild melena. There has been no treatment interrup-
tion by adverse events and also no hospitalization.
DISCUSSION
This study aimed at contributing to further know-
ledge about the effects of LC, which is a drug with 
high analgesic potential and good tolerability for 
elderly patients with knee OA-related pain. This is 
the first study using LC exclusively in the elderly 
population.
With regard to demographics, mean age was not 
very high: 72 years for LC group and 73 years 
for P group. There were more females and clear 
predominance of Caucasians, but the sample was 
homogeneous when comparing groups.
Still trying to characterize the sample, most severe 
pain associated to knee OA in different situations 
were protokinetic and ambulating pain. The pres-
ence of severe pain in these situations is a very im-
portant problem for the elderly, because it is known 
that pain at initial movement or at ambulation may 
predispose to falls by impairing balance17.
Most patients in both groups had no morning stiff-
ness or had it very briefly, so joint stiffness did not 
significantly impact the study. The same was true 
for pain-related functional incapacity because ma-
jor incapacities were only seen in a small percent-
age of individuals. That is, the most disabling form 
associated to pain was observed in only 2.75% of 
the elderly, and the considerable incapacity (impair-
ment of 3 DA) was present in 21.1% of cases. The 
tool used to evaluate pain-related incapacity was 
very practical to apply, but could pose some meth-
odological problem. There was agreement among 
authors who have also used it16 that the tool could 
not have been validated for joint pain purposes.
In this clinical trial, LC was more effective in de-
creasing pain at initial movement and at ambula-
tion: 42.3% decrease in protokinetic pain (p < 
0.001) and 45.5% at ambulation (p = 0.002). A 
significant improvement of this pain was already 
observed during the first 15 days of treatment, but 
best results were seen at the end of 30 days. So, an 
important data for symptomatic treatment of elder-
ly people with pain associated to knee OA, would 
be the use of LC for 30 days to have an optimized 
analgesia. In addition, protokinetic or at ambula-
tion pain relief could bring major benefits for the 
elderly, including less falls17.
LC was not more effective in decreasing pain at rest 
because both groups presented the same behavior 
along the study. The same was true for joint com-
pression pain. But for these two situations of OA 
pain, mean intensities were low in the beginning 
of the study (VAS of 6.7 mm and 8.9 mm at rest 
for LC and P groups, respectively, and VAS of 35.4 
mm and 35.9 mm at joint compression for LC and 
P groups, respectively) and this could have influ-
enced results.
In our study there has been less analgesic comple-
mentation to patients using LC (p = 0.021) and this 
could also represent a better analgesic action of 
such drug.
According to Fisher et al.18 there are fast onset an-
algesics, however with a therapeutic effect which 
may not be persistent. These agents, according to 
the same author, are the most widely used to treat 
symptomatic knee OA. Among major drugs used 
in the elderly with symptomatic knee OA there are 
dipirone acetaminophen and NSAIDs, however the 
latter are associated to major adverse events risk 
in such population, even when used for a short 
period19.
Some studies have shown that the clinical effi-
cacy of NSAIDs in equipotent doses is similar. 
However the individual response is highly vari-
able20. Variability of responses to NSAIDs in OA 
cannot be explained by the severity of the disease 
and the mechanism involved in these responses is 
not totally explained20. The better understanding 
of the effectiveness of different existing NSAIDs 
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used in different populations with knee OA-relat-
ed pain is of great importance because this way we 
could have more treatment options depending on 
patients’ profile.
Short clinical trial have shown that newest NSAIDs, 
especially coxibs, are effective for knee OA anal-
gesia and have good tolerability, but these have  not 
yet been addressed exclusively to the elderly popu-
lation21,22.
In a clinical trial with 3294 Brazilians with symp-
tomatic knee OA23, 49% of individuals showed ma-
jor pain improvement (at rest, initial movement, 
ambulation and joint compression) with the use of 
aceclofenac. However, this was not a controlled 
and randomized study and has not dealt exclusively 
with the elderly population.
Pain-related functional capacity did not improve 
in our study. Since it was a functionality evaluated 
for a very short period, it was to be expected that 
such functional improvement could not have oc-
curred. In a functionality evaluation in the elderly 
using the OARS Methodo logy16, demonstrations 
of pain improvement could favorably reflect in 
the global individual functionality, and the same 
has not been shown here in a statistically signifi-
cant way. So, a limitation of the study could be 
the functionality approach for a treatment for such 
a short period. In addition, more specific tools 
were not used, such as WOMAC (Western Ontario 
and McMaster Universities Osteoarthritis) Index, 
which has been used in clinical trials involving 
OA in the general population24.
There has been no significant improvement in mor-
ning stiffness with LC and this result is different 
from those found by some researchers with regard 
to knee OA. Eberhardt12 has shown that LC has sig-
nificantly improved morning stiffness, but meas-
urement was of stiffness intensity and not of its 
duration as it is our case. Since the beginning of the 
study, morning stiffness was not a frequent finding 
in its more severe form, that is, it has not frequently 
been presented with prolonged duration.
So, changes could not have been detected in a so in-
frequent finding. Global treatment evaluation was 
more favorable for patients receiving LC and this 
could be one more reflex of the higher LC analgesic 
effectiveness for knee OA in the elderly.
Treatment adhesion was considered very good and 
this is important because the difficult adherence to 
NSAIDs is known, especially in the elderly. When 
a high adhesion to a drug treatment is not achieved, 
it is inferred that it has not been effective, or even 
has caused major adverse reaction to the point of 
impairing adhesion.
LC tolerability criteria were similar to P (37.9% 
frequency of adverse events in LC group and 
23.1% in the placebo group; p = 0.124). In spite 
of the reasonable presence of undesirable effects 
with LC, most in the gastrointestinal tract, they 
were mild with no need for any specific treatment, 
especially with no need for any intervention (tran-
sient events with spontaneous resolution). Such 
results ratify the low incidence of adverse effects 
with LC12. A systematic review involving 16 clin-
ical trials with different NSAIDs, reported a rela-
tive risk of 2.74 (Confidence Interval (CI) 95%; 
2.54-2.97) for any gastrointestinal complication 
with NSAIDs11. In this same review addressing 
elderly people aged 65 years or more, the risk in-
creased to 5.52 (CI 95%; 4,63-6.60). A study on 
hospitalization caused by drug adverse reactions 
in the elderly aged 65 years or more has pointed 
NSAIDs as responsible for 23.5% of cases25. This 
way, we see how important it is that new drugs are 
studied in the elderly population, and that they do 
not increase the risks of complications, such as the 
hospitalization risk. 
Other limitation of our study was the small sample 
size, however we were able to show differences 
between treatments. In the elderly with knee OA-
related pain, LC was effective, that is, decreased 
protokinetic and ambulation pain and has led to 
a lower consumption of additional analgesics. In 
addition, LC treatment was globally considered 
good or excellent.
CONCLUSION 
LC was effective for the elderly with OA-related 
pain in relieving protokinetic and ambulation pain 
for a period of 15 days, and when used for 30 days, 
analgesia was optimized. Also a lower consumption 
of additional analgesics was observed with LC and 
global evaluation of LC treatment by the investiga-
tor was good or excellent. LC tolerability profile 
was highly reasonable for the elderly (lack of se-
vere adverse events) and there has been major ad-
herence to treatment.
We advocate the need for new clinical trials in Bra-
zil involving the elderly with chronic pain, such as 
Treatment of pain associated to knee osteoarthritis in  
the elderly: a randomized double-blind clinical trial with lysine clonixinate
Rev Dor. São Paulo, 2011 jan-mar;12(1):6-14
13
those with knee OA, and also that other effective 
analgesic drugs for such prevalent and disabling 
disease in the elderly are evaluated. This clinical 
trial with elderly people may contribute to meta-
analysis and systematic reviews involving gon-
arthrosis, because increasingly there is the need to 
carry out new randomized clinical trials addressing 
different populations.
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